Primobolan

Primobolan is the trade name for metenolone (also rendered methenolone), a synthetic androstane steroid derived from dihydrotestosterone (DHT) by introduction of a 1-methyl group and a 1,2-double bond into the A-ring of the 5-alpha-reduced androstane nucleus. The compound was first synthesized in 1960 and introduced for clinical use in 1961 by Squibb Pharmaceuticals in the United States (as Nibal and Nibal Depot) and by Schering AG in West Germany (as Primobolan and Primobolan Depot). Two ester prodrug forms are manufactured: metenolone acetate (CAS 434-05-9), the oral preparation with a molecular weight of 344.50 g/mol, and metenolone enanthate (CAS 303-42-4), the intramuscular depot preparation with a molecular weight of 414.63 g/mol. Both esters undergo hydrolysis in vivo to release the parent steroid metenolone (CAS 153-00-4; molecular formula C20H30O2; molecular weight 302.46 g/mol), which binds the androgen receptor with moderate affinity and produces anabolic effects in skeletal muscle, bone, and erythropoietic tissue.

The clinical pharmacology of metenolone is defined by several characteristics that distinguish it from structurally related anabolic-androgenic steroids. First, the compound is not 17-alpha-alkylated; the 1-methyl substitution and ester conjugation confer sufficient oral bioavailability (in the acetate form) and depot duration (in the enanthate form) without the hepatotoxic liability associated with C17-alpha-alkylated steroids such as oxymetholone, stanozolol, and methandrostenolone. Second, the 1,2-double bond and the DHT-derived backbone render metenolone resistant to aromatization by the cytochrome P450 aromatase enzyme complex (CYP19A1), eliminating estrogenic side effects including gynecomastia and estrogen-mediated fluid retention. Third, metenolone exhibits a moderate anabolic-to-androgenic dissociation ratio of approximately 88:44 to 150:50 in rodent bioassays (levator ani weight gain versus ventral prostate weight gain, relative to testosterone propionate as the reference standard), placing it in the class of mildly anabolic, mildly androgenic agents alongside oxandrolone and drostanolone.

The principal approved clinical indication was the treatment of anemia due to bone marrow failure, including aplastic anemia, myelofibrosis, and refractory cytopenias. A therapeutic trial reported by Compagno et al. (1978) in 19 consecutive patients with refractory anemia demonstrated remission in approximately 37 percent of patients with pancytopenia and variable responses across other cytopenia subtypes [1]. Additional historical indications included protein-calorie malnutrition, postoperative and post-infectious catabolic states, osteoporosis, sarcopenia, and promotion of weight gain in premature infants. The compound has been largely discontinued from clinical markets; as of the most recent monograph revision, metenolone enanthate is marketed only in Spain and Turkey (as Primobolan Depot), and metenolone acetate retains limited availability in Japan and Moldova.

Pharmacokinetics differ substantially between the two ester forms. Metenolone acetate is rapidly absorbed after oral administration but undergoes significant first-pass hepatic metabolism, resulting in reduced oral bioavailability relative to parenteral administration; the plasma half-life of the oral form is approximately 4 to 6 hours. Metenolone enanthate, administered by intramuscular injection in an oil vehicle, provides depot release with a biological half-life of approximately 10.5 days and a duration of action of approximately 14 days. Metabolism of metenolone proceeds through hepatic mixed-function oxidases; the principal urinary metabolite is 3-alpha-hydroxy-1-methylen-5-alpha-androstan-17-one, excreted as glucuronide and sulfate conjugates. The sulfate-conjugated metabolites provide extended detection windows in anti-doping analysis, with some metabolites detectable for several weeks after a single administration. Metenolone exhibits low affinity for sex hormone-binding globulin (SHBG), approximately 16 percent of that of testosterone and 3 percent of that of DHT, resulting in a higher fraction of unbound drug in plasma.

Adverse effects are consistent with the anabolic-androgenic steroid class but are generally milder than those of 17-alpha-alkylated compounds. Virilization in female patients (acne, hirsutism, voice deepening, clitoral enlargement, menstrual irregularity) is the principal androgenic concern. Suppression of endogenous gonadotropin secretion (luteinizing hormone and follicle-stimulating hormone) produces dose-dependent hypothalamic-pituitary-gonadal axis suppression with consequent testicular atrophy, oligospermia, and reduced endogenous testosterone production in male users. Cardiovascular effects include unfavorable shifts in the lipoprotein profile (decreased high-density lipoprotein cholesterol, increased low-density lipoprotein cholesterol), though these shifts are generally less pronounced than those produced by 17-alpha-alkylated oral steroids. Hepatotoxicity is minimal at therapeutic doses, consistent with the absence of C17-alpha-alkylation. This monograph reviews the chemistry, synthesis, and structural pharmacology of metenolone; the androgen receptor mechanism and tissue-selective pharmacodynamics; the complete pharmacokinetic profile of both ester forms; the clinical evidence base across hematologic, catabolic, and body-composition indications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events; and a comparative assessment of five alternative anabolic-androgenic steroids against Primobolan on five competency standards.